PELI2

Summary

PELI2 (pellino E3 ubiquitin protein ligase family member 2, HGNC:8828) is a protein-coding gene on chromosome 14q22.3, encoding E3 ubiquitin-protein ligase pellino homolog 2 (Q9HAT8). E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins.

Predicted to enable protein-macromolecule adaptor activity and ubiquitin protein ligase activity. Acts upstream of or within positive regulation of MAPK cascade and positive regulation of protein phosphorylation. Predicted to be located in cytosol.

Source: NCBI Gene 57161 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 65 total
• MANE Select transcript: NM_021255

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8828
Approved symbol	PELI2
Name	pellino E3 ubiquitin protein ligase family member 2
Location	14q22.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000139946
Ensembl biotype	protein_coding
OMIM	614798
Entrez	57161

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000267460, ENST00000559044, ENST00000561019, ENST00000705193

RefSeq mRNA: 1 — MANE Select: NM_021255 NM_021255

CCDS: CCDS9726

Canonical transcript exons

ENST00000267460 — 6 exons

Exon	Start	End
ENSE00001093822	56288437	56288634
ENSE00001093824	56290268	56290456
ENSE00001193572	56296600	56301524
ENSE00001259120	56118411	56118737
ENSE00003469520	56279676	56279777
ENSE00003590243	56178335	56178464

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 96.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.7120 / max 401.6199, expressed in 1341 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139758	10.4547	1303
139759	0.4700	227
139757	0.4556	237
139766	0.2548	141
139756	0.0468	15
139755	0.0300	9

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	96.60	gold quality
cortical plate	UBERON:0005343	92.78	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	91.49	gold quality
ganglionic eminence	UBERON:0004023	91.18	gold quality
calcaneal tendon	UBERON:0003701	91.12	gold quality
jejunal mucosa	UBERON:0000399	90.63	gold quality
monocyte	CL:0000576	88.13	gold quality
mononuclear cell	CL:0000842	88.03	gold quality
body of pancreas	UBERON:0001150	87.94	gold quality
leukocyte	CL:0000738	87.68	gold quality
metanephric glomerulus	UBERON:0004736	86.30	gold quality
blood	UBERON:0000178	86.18	gold quality
sural nerve	UBERON:0015488	86.09	gold quality
pigmented layer of retina	UBERON:0001782	86.01	gold quality
retina	UBERON:0000966	85.99	gold quality
nephron tubule	UBERON:0001231	85.53	gold quality
hair follicle	UBERON:0002073	85.42	silver quality
embryo	UBERON:0000922	85.31	gold quality
visceral pleura	UBERON:0002401	85.24	gold quality
pancreas	UBERON:0001264	85.20	gold quality
renal glomerulus	UBERON:0000074	85.03	gold quality
tendon	UBERON:0000043	84.34	gold quality
bone marrow	UBERON:0002371	83.90	gold quality
left ovary	UBERON:0002119	83.69	gold quality
buccal mucosa cell	CL:0002336	83.68	gold quality
tibia	UBERON:0000979	83.49	gold quality
ovary	UBERON:0000992	83.09	gold quality
mucosa of urinary bladder	UBERON:0001259	82.69	silver quality
kidney epithelium	UBERON:0004819	82.54	gold quality
popliteal artery	UBERON:0002250	82.49	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.85

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

228 targeting PELI2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-373-5P	99.98	75.36	4753

Literature-anchored findings (GeneRIF, showing 9)

• interacts with TRAF6 (tumor necrosis factor receptor associated factor 6) and TAK1 (transforming growth factor-beta activated kinase 1); can activate the mitogen activated protein kinase pathway (PMID:12804775)
• Pellino2 interacts with kinase-active as well as kinase-inactive IRAK1 and IRAK4 (PMID:12860405)
• Pellino 2 plays a critical role for TLR/IL-1R-mediated post-transcriptional control. (PMID:22669975)
• A high-affinity Pellino2 e3 ubiquitin ligase binding domain is specific for phosphothreonine motifs. (PMID:25027698)
• K(+) regulates relocation of Pellino-2 to the site of NLRP3 inflammasome activation in macrophages. (PMID:34387857)
• Pellino-2 in nonimmune cells: novel interaction partners and intracellular localization. (PMID:34674267)
• A Pellino-2 variant is associated with constitutive NLRP3 inflammasome activation in a family with ocular pterygium-digital keloid dysplasia. (PMID:36776133)
• PELI2 regulates early B-cell progenitor differentiation and related leukemia via the IL-7R expression. (PMID:38058209)
• PELI2 is a negative regulator of STING signaling that is dynamically repressed during viral infection. (PMID:38917796)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000003041
danio_rerio	peli2	ENSDARG00000029045
mus_musculus	Peli2	ENSMUSG00000021846
rattus_norvegicus	Peli2	ENSRNOG00000012363
drosophila_melanogaster	Pli	FBGN0025574
caenorhabditis_elegans		WBGENE00017766

Paralogs (2): PELI3 (ENSG00000174516), PELI1 (ENSG00000197329)

Protein

Protein identifiers

E3 ubiquitin-protein ligase pellino homolog 2 — Q9HAT8 (reviewed: Q9HAT8)

Alternative names: RING-type E3 ubiquitin transferase pellino homolog 2

All UniProt accessions (4): Q9HAT8, A0A994J4T1, H0YK56, H0YNF4

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates IL1B-induced IRAK1 ‘Lys-63’-linked polyubiquitination and possibly ‘Lys-48’-linked ubiquitination. May be important for LPS- and IL1B-induced MAP3K7-dependent, but not MAP3K3-dependent, NF-kappa-B activation. Can activate the MAP (mitogen activated protein) kinase pathway leading to activation of ELK1.

Subunit / interactions. Interacts with TRAF6, IRAK1, IRAK4 and MAP3K7. Interacts with BCL10; this interaction is impaired by SOCS3.

Post-translational modifications. Phosphorylated by IRAK1 and IRAK4 enhancing its E3 ligase activity.

Domain organisation. The atypical FHA domain contains a ‘wing’ insert and mediates binding to threonine-phosphorylated IRAK1.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the pellino family.

RefSeq proteins (1): NP_067078* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006800	Pellino_fam	Family
IPR048334	Pellino_FHA	Domain
IPR048335	Pellino_RING	Domain

Pfam: PF04710, PF20723

UniProt features (28 total): strand 18, mutagenesis site 5, helix 3, chain 1, domain 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
3EGA	X-RAY DIFFRACTION	1.8
3EGB	X-RAY DIFFRACTION	3.25

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HAT8-F1	89.87	0.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (5):

Position	Phenotype
106	abolishes binding to irak1.
187	abolishes binding to irak1; when associated with a-188.
188	abolishes binding to irak1; when associated with a-187.
397	loss of irak1-polyubiquitination.
400	loss of irak1-polyubiquitination.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9020702	Interleukin-1 signaling
R-HSA-937039	IRAK1 recruits IKK complex
R-HSA-975144	IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation

MSigDB gene sets: 261 (showing top): FREAC2_01, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_PHOSPHORYLATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GCANCTGNY_MYOD_Q6, AAGCCAT_MIR135A_MIR135B, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, SRF_Q5_01, NKX62_Q2, SOX9_B1, FREAC3_01, DOANE_RESPONSE_TO_ANDROGEN_DN, GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS

GO Biological Process (6): protein polyubiquitination (GO:0000209), positive regulation of protein phosphorylation (GO:0001934), regulation of Toll signaling pathway (GO:0008592), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), positive regulation of MAPK cascade (GO:0043410), protein ubiquitination (GO:0016567)

GO Molecular Function (4): ubiquitin-ubiquitin ligase activity (GO:0034450), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Interleukin-1 family signaling	1
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	1
MyD88 cascade initiated on plasma membrane	1
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of intracellular signal transduction	2
protein ubiquitination	1
regulation of protein phosphorylation	1
protein phosphorylation	1
positive regulation of protein modification process	1
positive regulation of phosphorylation	1
Toll signaling pathway	1
regulation of signal transduction	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
MAPK cascade	1
regulation of MAPK cascade	1
protein modification by small protein conjugation	1
ubiquitin protein ligase activity	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

734 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PELI2	IRAK1	P51617	958
PELI2	IRAK4	Q9NWZ3	844
PELI2	TRAF6	Q9Y4K3	813
PELI2	IL1R1	P14778	592
PELI2	MYD88	P78397	586
PELI2	TOLLIP	Q9H0E2	583
PELI2	TLR4	O00206	581
PELI2	TAB2	Q9NYJ8	517
PELI2	SMAD6	O43541	502
PELI2	TAB1	Q15750	494
PELI2	MARCHF7	Q9H992	492
PELI2	ECSIT	Q9BQ95	489
PELI2	UBE2N	P61088	487
PELI2	CASP8	Q14790	486
PELI2	BCL2	P10415	477

IntAct

70 interactions, top by confidence:

A	B	Type	Score
IRAK1	PELI2	psi-mi:“MI:0915”(physical association)	0.740
PELI2	IRAK1	psi-mi:“MI:0915”(physical association)	0.740
PELI2	IRAK4	psi-mi:“MI:0915”(physical association)	0.590
IRAK4	PELI2	psi-mi:“MI:0217”(phosphorylation reaction)	0.590
PELI2	PCGF2	psi-mi:“MI:0915”(physical association)	0.560
TP63	PELI2	psi-mi:“MI:0915”(physical association)	0.560
MEOX1	PELI2	psi-mi:“MI:0915”(physical association)	0.560
PELI2	SEPTIN3	psi-mi:“MI:0915”(physical association)	0.560
MDFI	PELI2	psi-mi:“MI:0915”(physical association)	0.560
RABEP1	PELI2	psi-mi:“MI:0915”(physical association)	0.560
TMEM79	PELI2	psi-mi:“MI:0915”(physical association)	0.560
REL	PELI2	psi-mi:“MI:0915”(physical association)	0.560
CLEC17A	PELI2	psi-mi:“MI:0915”(physical association)	0.560
TRIM32	PELI2	psi-mi:“MI:0915”(physical association)	0.560
SP4	PELI2	psi-mi:“MI:0915”(physical association)	0.560
PELI2	LZTFL1	psi-mi:“MI:0915”(physical association)	0.560
OR7D2	PELI2	psi-mi:“MI:0915”(physical association)	0.560
HYAL2	PELI2	psi-mi:“MI:0915”(physical association)	0.560
PCGF2	PELI2	psi-mi:“MI:0915”(physical association)	0.560
NUP62	PELI2	psi-mi:“MI:0915”(physical association)	0.560
RMDN3	PELI2	psi-mi:“MI:0915”(physical association)	0.560
PELI2		psi-mi:“MI:0407”(direct interaction)	0.440
PELI2	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
PELI2	FN1	psi-mi:“MI:0915”(physical association)	0.370
HNRNPK	PELI2	psi-mi:“MI:0915”(physical association)	0.370
PELI2	LTBP3	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (80): IRAK1 (Affinity Capture-Western), UQCRFS1 (Affinity Capture-Western), TRAF6 (Affinity Capture-Western), PELI2 (Affinity Capture-RNA), PELI2 (Protein-peptide), PELI2 (Two-hybrid), PELI2 (Two-hybrid), PELI2 (Two-hybrid), PELI2 (Two-hybrid), PELI2 (Two-hybrid), PELI2 (Two-hybrid), PELI2 (Two-hybrid), PELI2 (Two-hybrid), PELI2 (Two-hybrid), REL (Two-hybrid)

ESM2 similar proteins: A0JN39, A4FUD6, B1H2N3, D2SW95, D2XV59, O00178, O08582, O35218, O60941, O77237, P11029, P11497, P23514, P29144, P42694, P53618, Q0J035, Q0JNK5, Q13085, Q28559, Q53PC7, Q58DC5, Q5R4J9, Q5R922, Q5RCC1, Q5SWU9, Q5T5C0, Q5XGS8, Q5ZIA5, Q5ZM73, Q6DFV5, Q6NYU2, Q80UM3, Q80YV4, Q8BHL5, Q8BST6, Q8BXR6, Q8C669, Q8IZH2, Q8L5Y9

Diamond homologs: O77237, Q8BST6, Q8BXR6, Q8C669, Q8N2H9, Q96FA3, Q9HAT8

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
IRAK4	up-regulates	PELI2	phosphorylation
PELI2	up-regulates	IRAK1	ubiquitination
PELI2	“up-regulates activity”	NLRP3	ubiquitination
IRAK1	“up-regulates activity”	PELI2	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 31 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of canonical NF-kappaB signal transduction	5	11.7×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2148 predictions. Top by Δscore:

Variant	Effect	Δscore
14:56118734:TCGGG:T	donor_loss	1.0000
14:56118735:CGGG:C	donor_loss	1.0000
14:56118736:GG:G	donor_gain	1.0000
14:56118736:GGGT:G	donor_loss	1.0000
14:56118737:GG:G	donor_gain	1.0000
14:56178326:T:A	acceptor_gain	1.0000
14:56178330:TCTA:T	acceptor_loss	1.0000
14:56178331:CTAG:C	acceptor_loss	1.0000
14:56178332:TA:T	acceptor_loss	1.0000
14:56178333:A:AG	acceptor_gain	1.0000
14:56178333:A:C	acceptor_loss	1.0000
14:56178333:AG:A	acceptor_gain	1.0000
14:56178334:G:GA	acceptor_gain	1.0000
14:56178334:GG:G	acceptor_gain	1.0000
14:56178334:GGT:G	acceptor_gain	1.0000
14:56178334:GGTA:G	acceptor_gain	1.0000
14:56178334:GGTAC:G	acceptor_gain	1.0000
14:56178462:AAGG:A	donor_loss	1.0000
14:56178464:GGTA:G	donor_loss	1.0000
14:56178465:G:T	donor_loss	1.0000
14:56279674:A:AG	acceptor_gain	1.0000
14:56279675:G:GG	acceptor_gain	1.0000
14:56279773:TTCAG:T	donor_loss	1.0000
14:56279774:TCAG:T	donor_loss	1.0000
14:56279775:CAGGT:C	donor_loss	1.0000
14:56279776:AGG:A	donor_loss	1.0000
14:56279777:GGTAA:G	donor_loss	1.0000
14:56279778:G:GA	donor_loss	1.0000
14:56279779:TAATA:T	donor_loss	1.0000
14:56288434:TA:T	acceptor_loss	1.0000

AlphaMissense

2764 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:56118718:G:T	G20W	1.000
14:56118719:G:A	G20E	1.000
14:56118725:T:C	L22P	1.000
14:56118736:G:T	G26W	1.000
14:56118737:G:A	G26E	1.000
14:56178415:G:A	G53D	1.000
14:56178418:T:A	V54D	1.000
14:56279704:T:A	I79K	1.000
14:56279704:T:G	I79R	1.000
14:56279709:T:G	Y81D	1.000
14:56279722:G:T	R85M	1.000
14:56279745:T:C	Y93H	1.000
14:56279745:T:G	Y93D	1.000
14:56279777:G:C	Q103H	1.000
14:56279777:G:T	Q103H	1.000
14:56288440:G:A	G105S	1.000
14:56288440:G:C	G105R	1.000
14:56288440:G:T	G105C	1.000
14:56288441:G:A	G105D	1.000
14:56288441:G:T	G105V	1.000
14:56288443:A:G	R106G	1.000
14:56288444:G:C	R106T	1.000
14:56288444:G:T	R106I	1.000
14:56288445:A:C	R106S	1.000
14:56288445:A:T	R106S	1.000
14:56288446:T:C	S107P	1.000
14:56288461:A:T	I112F	1.000
14:56288465:A:T	D113V	1.000
14:56288471:T:A	V115D	1.000
14:56288474:T:A	V116D	1.000

dbSNP variants (sampled 300 via entrez): RS1000010466 (14:56192135 G>A), RS1000021348 (14:56152542 A>C,T), RS1000026695 (14:56172797 A>G), RS1000035918 (14:56120630 G>C), RS1000038117 (14:56146222 C>A), RS1000039336 (14:56230242 A>G), RS1000089947 (14:56145972 T>C), RS1000091348 (14:56153916 G>A), RS1000122369 (14:56145487 C>A), RS1000148141 (14:56269235 G>A), RS1000166845 (14:56150051 C>T), RS1000216663 (14:56169470 C>G,T), RS1000226510 (14:56232952 T>G), RS1000230540 (14:56198011 C>T), RS1000237817 (14:56232736 A>C,G)

Disease associations

OMIM: gene MIM:614798 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001024_2	Telomere length	2.000000e-06
GCST001737_32	Chronic obstructive pulmonary disease-related biomarkers	6.000000e-06
GCST002573_2	Height	9.000000e-07
GCST002928_20	Nickel levels	4.000000e-06
GCST004581_2	Body mass index (smoking years interaction)	6.000000e-07
GCST004586_1	Body mass index (ever vs never smoking interaction)	2.000000e-06
GCST008395_9	End-stage kidney disease	9.000000e-07
GCST009153_7	Adverse response to chemotherapy (amenorrhea) in breast cancer	9.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression, increases methylation	4
sodium arsenite	decreases expression, increases expression	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Cisplatin	decreases expression, increases expression	2
Nickel	decreases expression	2
Tobacco Smoke Pollution	increases expression	2
Cyclosporine	increases expression	2
GSK-J4	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
aflatoxin B2	increases methylation	1
di-n-butylphosphoric acid	affects expression	1
clothianidin	decreases expression	1
NSC668394	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Glyphosate	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression, increases abundance	1
Tetrachlorodibenzodioxin	increases expression	1
Tretinoin	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.